Cosmetic cross-reference Noindex: medium evidence

3012-65-5

CAS 3012-65-5

3012-65-5 (CAS 3012-65-5) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
3012-65-5
CAS Number
3012-65-5
UNII
N9BUG430K8
InChIKey
YXVFQADLFFNVDS-UHFFFAOYSA-N
ChEMBL ID
CHEMBL3189066
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 3012-65-5 used for in pharmaceutical contexts?

3012-65-5 (CAS 3012-65-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 3012-65-5?

No adverse-event association or SIDER side-effect rows are rendered for 3012-65-5 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 3012-65-5 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Diammonium Citrate with EU status "permitted".

What clinical phase is 3012-65-5 in?

No phase 1-4 clinical development badge is rendered for 3012-65-5 because the matched compound identifier rows do not contain a max-phase value.